Compounds > salinosporamide b

Page last updated: 2024-11-12

salinosporamide b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

salinosporamide B: from the marine Actinomycete Salinispora tropica; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	11173518
CHEMBL ID	371634
CHEBI ID	48047
SCHEMBL ID	6380707
MeSH ID	M0490735

Synonyms (17)

Synonym
(1r,4r,5s)-4-ethyl-1-((s)-((s)-cyclohex-2-enyl)(hydroxy)methyl)-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
salinosporamide b
CHEBI:48047 ,
(1r,4r,5s)-1-[(s)-(1s)-cyclohex-2-en-1-yl(hydroxy)methyl]-4-ethyl-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
CHEMBL371634
(1r,4r,5s)-1-((s)-(1s)-2-cyclohexen-1-ylhydroxymethyl)-4-ethyl-5-methyl-6-oxa-2-azabicyclo(3.2.0)heptane-3,7-dione
npi-0047
863126-95-8
unii-f8b5995w5r
f8b5995w5r ,
6-oxa-2-azabicyclo(3.2.0)heptane-3,7-dione, 1-((s)-(1s)-2-cyclohexen-1-ylhydroxymethyl)-4-ethyl-5-methyl-, (1r,4r,5s)-
salinosporamide b [mi]
SCHEMBL6380707
Q27120918
(1r,4r,5s)-1-[[(1s)-cyclohex-2-en-1-yl]-hydroxymethyl]-4-ethyl-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
(1r,4r,5s)-1-[(s)-[(1s)-cyclohex-2-en-1-yl]-hydroxymethyl]-4-ethyl-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
AKOS040753903

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
salinosporamide	Family of cytotoxic secondary metabolites produced by the marine actinomycete Salinispora tropica.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (15)

Assay ID	Title	Year	Journal	Article
AID390512	Inhibition of caspase-like activity of rabbit 20S proteasome assessed as enzyme activity recovery 12 hrs after dialysis	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID390501	Inhibition of chymotrypsin-like activity of yeast 20S proteasome	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID240482	Inhibition of NF-kB activation in HEK293 cells	2005	Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11	Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor.
AID240556	Inhibition of caspase-like (CA-L) activity of rabbit 20S proteasome	2005	Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11	Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor.
AID390500	Inhibition of caspase-like activity of rabbit 20S proteasome	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID390502	Inhibition of trypsin-like activity of yeast 20S proteasome	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID390508	Inhibition of chymotrypsin-like activity of rabbit 20S proteasome assessed as enzyme activity recovery 12 hrs after dialysis	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID247472	Cytotoxic activity against RPMI 8226 cells	2005	Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11	Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor.
AID390503	Inhibition of caspase-like activity of yeast 20S proteasome	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID390497	Stability in 20 mM HEPES buffer assessed as beta-lactone hydrolysis rate at pH 7.3 at 27 degC	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID240557	Inhibition of chymotrypsin-like (CT-L) activity of rabbit 20S proteasome	2005	Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11	Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor.
AID240539	Inhibition of trypsin-like (T-L) activity of rabbit 20S proteasome	2005	Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11	Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor.
AID390499	Inhibition of trypsin-like activity of rabbit 20S proteasome	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID390498	Inhibition of chymotrypsin-like activity of rabbit 20S proteasome	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
AID390511	Inhibition of trypsin-like activity of rabbit 20S proteasome assessed as enzyme activity recovery 12 hrs after dialysis	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	8 (88.89)	29.6817
2010's	1 (11.11)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.95 (24.57)
Research Supply Index	2.30 (2.92)
Research Growth Index	4.26 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.95)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	9 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
butyric acid Butyric Acid: A four carbon acid, CH3CH2CH2COOH, with an unpleasant odor that occurs in butter and animal fat as the glycerol ester.. butyrate : A short-chain fatty acid anion that is the conjugate base of butyric acid, obtained by deprotonation of the carboxy group.. butyric acid : A straight-chain saturated fatty acid that is butane in which one of the terminal methyl groups has been oxidised to a carboxy group.	2.03	1	0	fatty acid 4:0; straight-chain saturated fatty acid	human urinary metabolite; Mycoplasma genitalium metabolite
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	3.3	6	0	pyrrole; secondary amine
cobalt Cobalt: A trace element that is a component of vitamin B12. It has the atomic symbol Co, atomic number 27, and atomic weight 58.93. It is used in nuclear weapons, alloys, and pigments. Deficiency in animals leads to anemia; its excess in humans can lead to erythrocytosis.. cobalt(1+) : A monovalent inorganic cation obtained from cobalt.. cobalt atom : A cobalt group element atom that has atomic number 27.	2.05	1	0	cobalt group element atom; metal allergen	micronutrient
clasto-lactacystin beta-lactone clasto-lactacystin beta-lactone: active metabolite of lactacystin; inhibits 20 S proteasome; structure in first source	2.94	1	0
marizomib marizomib: a proteasome inhibitor from a marine bacterium Salinospora; structure in first source	4.46	8	0	beta-lactone; gamma-lactam; organic heterobicyclic compound; organochlorine compound; salinosporamide	antineoplastic agent; proteasome inhibitor
fluorosalinosporamide fluorosalinosporamide: structure in first source	2.44	2	0
vitamin b 12 Vitamin B 12: A cobalt-containing coordination compound produced by intestinal micro-organisms and found also in soil and water. Higher plants do not concentrate vitamin B 12 from the soil and so are a poor source of the substance as compared with animal tissues. INTRINSIC FACTOR is important for the assimilation of vitamin B 12.	2.05	1	0